CDMO（合約開發和製造組織）的日本市場規模、佔有率和趨勢分析報告：按產品、工作流程、用途和細分市場進行預測，2023-2030年

CDMO（合約開發和製造組織）的日本市場成長和趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年CDMO（合約開發和製造組織）的日本市場規模將達到195億美元，2023年至2030年年複合成長率為5.9%。

該市場的主要驅動力是合約開發和製造組織（CDMO）為擴大產能而增加投資，日本人口老化和疾病負擔增加以及藥品製造和開發服務外包相關成本較低。

COVID-19大流行增加了CDMO市場的需求。即使在大流行期間，日本的一些 CDMO 也希望透過擴張設施來提高其能力。例如，Bushu Pharmaceutical於2020年8月擴建了Misato工廠設施，成為無菌藥品和生技藥品的專用溫控儲存設施。同樣，2020年7月，CMIC集團在日本新設置了一家新工廠，專門從事抗體醫藥品的加工開發和GMP製造。國內CDMO的這些配合措施預計將對市場產生正面影響。

市場參與企業繼續採取重大策略配合措施，包括設施擴建、聯盟、合作夥伴關係、新服務推出和併購。例如，2020年5月，臨床供應服務市場的領導者Catalent宣布計劃從Teva 工業（愛知縣名古屋市）收購臨床包裝設施。此次收購將創建一個新的臨床 GMP 生產和分銷基地，以支援臨床研究。此外，2022年7月，Catalent宣布將在滋賀縣建造一條高速泡殼包裝線。這將添加到自動化填充生產設施中。

日本的CDMO（合約開發和製造組織）市場報告亮點：

• 到2022年，API 產品將佔據最大的銷售佔有率，達到 81.0%。產品區隔分為原料藥及醫藥產品。
• 依用途，商業細分市場在2022年佔據最大收益佔有率，達到 88.0%。這是由於對學名藥的需求增加，而慢性病的高負擔也促進了成長。
• 預計腫瘤學領域在預測期內的年複合成長率將達到 6.4%，是最快的。這是因為由於日本癌症患者數量的增加，對新的癌症治療藥物的需求日益增加。
• 2020年11月，WuXi AppTec擴大了其細胞和基因治療平台提供的服務。該平台能夠更快、高預測可能性地開發、製造和引進細胞和基因療法。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 日本的CDMO（合約開發與製造組織）市場變數、趨勢與範圍

• 市場體系展望
  • 母市場展望
  • 相關/附隨市場展望
• 普及和成長前景圖
• 市場動態
  • 市場促進因素分析
  • 市場抑制因素分析
• 日本的CDMO（合約開發與製造組織）市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析

第4章 日本的CDMO（合約開發和製造組織）：依產品估算和趨勢分析

• 日本的CDMO（合約開發與製造組織）市場：要點
• 日本的CDMO（合約開發和製造組織）市場：2022年和2030年趨勢和市場佔有率分析
• API
  • 2018年至2030年原料藥市場預測
  • 類型
  • 合成
  • 藥品
  • 製造業
• 藥品
  • 2018年至2030年醫藥市場預測
  • 口服固態給藥
  • 半固體給藥
  • 液體給藥
  • 其他

第5章 日本的CDMO（合約開發與製造組織）：依工作流程進行估算與趨勢分析

• 日本的CDMO（合約開發與製造組織）市場：要點
• 日本的CDMO（合約開發和製造組織）市場：2022年和2030年趨勢和市場佔有率分析
• 臨床
• 商業

第6章 日本的CDMO（合約開發與製造組織）：依用途進行估算和趨勢分析

• 日本的CDMO（合約開發與製造組織）市場：要點
• 日本的CDMO（合約開發和製造組織）市場：2022年和2030年趨勢和市場佔有率分析
• 腫瘤學
• 荷爾蒙
• 青光眼
• 循環系統疾病
• 糖尿病
• 其他

第7章 競爭形勢

• 主要市場參與企業的最新趨勢和影響分析
• 市場參與企業分類

Japan Contract Development And Manufacturing Organization Market Growth & Trends:

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights:

• The API product segment accounted for the largest revenue share of 81.0% in 2022. The product segment is divided into API and drug product
• Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
• The oncology segment is anticipated to register the fastest CAGR of 6.4% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
• In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Workflow
  • 1.1.3. Application
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Workflow
  • 2.2.3. Application
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis

• 4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. API
  • 4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.2. Type
    • 4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
    • 4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
    • 4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.4. Antibody drug conjugate (ADC)
    • 4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2.5. Others
    • 4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.3. Synthesis
    • 4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.2. Synthetic
    • 4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.3. Solid
    • 4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.4. Liquid
    • 4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3.5. Biotech
    • 4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.4. Drug
    • 4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4.2. Innovative
    • 4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4.3. Generic
    • 4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.3.5. Manufacturing
    • 4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5.2. Continuous manufacturing
    • 4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5.3. Batch manufacturing
    • 4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Drug Product
  • 4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Oral solid dose
    • 4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Semi-solid dose
    • 4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Liquid dose
    • 4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis

• 5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Clinical
  • 5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Commercial
  • 5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis

• 6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
• 6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Oncology
  • 6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Hormonal
  • 6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Glaucoma
  • 6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Cardiovascular Disease
  • 6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Diabetes
  • 6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. CORDENPHARMA INTERNATIONAL
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. WuXi AppTec
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Cambrex Corporation
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Recipharm AB
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Lonza
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Catalent, Inc.
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Laboratory Corporation of America Holdings
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Thermo Fisher Scientific, Inc
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Samsung BioLogics
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. CMIC HOLDINGS Co., LTD
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. Bushu Pharmaceuticals LTD.
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. NIPRO
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives

List of Tables

• Table 1 List of Abbreviations
• Table 2 Japan contract development and manufacturing organization market, by product, 2018 - 2030 (USD Million)
• Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 - 2030 (USD Million)
• Table 4 Japa contract development and manufacturing organization market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Japan contract development and manufacturing organization: Market outlook
• Fig. 9 Japan contract development and manufacturing organization: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Japan contract development and manufacturing organization market driver impact
• Fig. 15 Japan contract development and manufacturing organization market restraint impact
• Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
• Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
• Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
• Fig. 19 API market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Type market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Solid market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Drug market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Drug product market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
• Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
• Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
• Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
• Fig. 47 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Others market estimates and forecasts, 2018 - 2030 (USD Million)